We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Pfizer Inc | LSE:0Q1N | London | Ordinary Share | PFIZER ORD (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.80 | 3.06% | 26.95 | 24.40 | 29.50 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 51,021 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 58.5B | 2.12B | 0.3753 | 70.98 | 147.65B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/2/2025 | 14:26 | ALNC |  Pfizer returns to profit in fourth quarter as revenue rises |
| 15/1/2025 | 08:43 | ALNC | UPDATE: Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale |
| 14/1/2025 | 17:24 | ALNC | Pfizer to more than halve Haleon holding in GBP2.57 billion sale |
| 17/12/2024 | 13:42 | ALNC | Pfizer's 2025 outlook meets hopes, eyes margin boost and cost savings |
| 29/10/2024 | 14:31 | ALNC | Hundreds of blood cancer patients to benefit from new Pfizer treatment |
| 29/10/2024 | 11:46 | ALNC | TOP NEWS: Pfizer swings to third-quarter profit as Paxlovid sales jump |
| 03/10/2024 | 16:29 | ALNC | IN BRIEF: Haleon buys GBP230 million in shares from Pfizer |
| 01/10/2024 | 09:03 | ALNC | UPDATE: Pfizer cuts stake in Haleon to 15% with GBP2.7 billion sale |
| 30/9/2024 | 20:59 | ALNC | TOP NEWS: Pfizer to raise around GBP2.7 billion from Haleon stake sale |
| 25/9/2024 | 12:49 | ALNC | Pfizer, Moderna and BioNTech take patent fight to Court of Appeal |
1 Year Pfizer Chart |
Intraday Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
